Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed.
Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective than placebo in inducing clinical remission at week 6 in patients with Crohn’s disease in whom previous treatment with tumor necrosis factor antagonists had failed.
However, at week 10, a higher proportion of patients given vedolizumab were in remission (26.6%) than of those given placebo (12.1%). Also, a higher proportion of patients with previous TNF antagonist failure given vedolizumab had a ≥100-point decrease in Crohn’s disease activity score at week 6 than those given placebo (39.2% vs 22.3%). Adverse events were similar between groups.
In the podcast, Sands says that these results show that patients with refractory disease might need to be treated for a longer period—it might not be clear until weeks 6–10 that vedolizumab will induce clinical remission.